AgeX Therapeutics Reports Second Quarter 2022 Financial Results
August 13, 2022ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.
Liquidity and Capital Resources
During the first quarter of 2022, AgeX borrowed the final $0.5 million of its available credit under its 2020 Secured Convertible Facility Agreement with Juvenescence Limited (“Juvenescence”), and entered into a new Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence has agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the principal and the loan origination fees under its 2019 Loan Agreement with Juvenescence.
During the three months ended June 30, 2022, AgeX borrowed an additional $2.0 million under the Secured Note, and as of August 12, 2022, AgeX had borrowed at total of $10,160,000 with $3.0 million of funds remaining for future borrowings under the Secured Note. The remaining line of credit available may be drawn down from time to time until February 14, 2023 subject to Juvenescence’s discretion to approve each loan draw. The outstanding principal balance of the Secured Note will become due and payable on February 14, 2024.
In addition, AgeX may sell shares of its common stock in “at-the-market” transactions through a Sales Agreement with Chardan Capital, LLC as a sales agent. The market value of common shares that AgeX may sell in any 12 month period during the term of the Sales Agreement will be limited to one-third of aggregate market value of AgeX common stock held by stockholders who would not be considered “affiliates” of AgeX, determined in accordance with applicable SEC rules.
Going Concern Considerations
As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeX’s most recent projected cash flows, AgeX believes that its cash and cash equivalents and available sources of debt and equity capital would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the twelve months following the filing of AgeX’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2022. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.
Balance Sheet Information
Cash, and cash equivalents, and restricted cash totaled $0.8 million as of June 30, 2022.
Second Quarter 2022 Operating Results
The following comparisons exclude the impact of the operations of AgeX’s former subsidiary LifeMap Sciences, Inc. (“LifeMap Sciences”) which have been presented in AgeX’s consolidated financial results as discontinued operations for all periods presented due to the disposition of AgeX’s shares of LifeMap Sciences in a cash-out merger during March 2021.
Revenues: Total revenues for the second quarter of 2022 were $12,000 as compared with $37,000 for the second quarter of 2021, primarily due to decreased sales of research products and the expiration of a research grant from the NIH that had been available during 2021.
Operating expenses: Operating expenses for the three months ended June 30, 2022 were $1.6 million as compared to $2.2 million for the same period in 2021.
Research and development expenses decreased to $0.3 million during the three months ended June 30, 2022 from $0.5 million during the same period of 2021 primarily reflecting a reduction of $0.2 million in scientific consulting and outside research and service and patent related expenses under a sponsored research agreement with a university.
General and administrative expenses decreased to $1.3 million during the three months ended June 30, 2022 from $1.7 million during the same period in 2021. The $0.4 million decrease is primarily attributable to decreases of $0.1 million in each of the following expense categories: professional fees for legal services, consulting expenses, noncash stock-based compensation expense to directors, and annual minimum royalties due under license agreements.
Other expense, net: Total other expense, net for the three months ended June 30, 2022 consists primarily of $0.9 million amortization of deferred debt issuance costs to interest expense and other debt related expenses included in interest expense and $0.2 million unrealized loss on change in fair value of warrants issued to Juvenescence in connection with borrowings under the Secured Note. Total other expense, net for the three months ended June 30, 2021 consists primarily of $0.3 million amortization of deferred debt issuance costs to interest expense.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX’s PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem® is AgeX’s delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
|
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value amounts) |
||||||||
|
|
|
June 30, 2022 |
|
|
December 31, 2021 |
|
||
|
|
|
(unaudited) |
|
|
|
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
702 |
|
|
$ |
584 |
|
|
Accounts and grants receivable, net |
|
|
12 |
|
|
|
25 |
|
|
Prepaid expenses and other current assets |
|
|
1,011 |
|
|
|
1,625 |
|
|
Total current assets |
|
|
1,725 |
|
|
|
2,234 |
|
|
|
|
|
|
|
|
|
|
|
|
Deposits |
|
|
50 |
|
|
|
50 |
|
|
Intangible assets, net |
|
|
804 |
|
|
|
870 |
|
|
TOTAL ASSETS |
|
$ |
2,579 |
|
|
$ |
3,154 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
682 |
|
|
$ |
771 |
|
|
Loan due to Juvenescence, net of debt issuance costs, current portion |
|
|
6,968 |
|
|
|
7,140 |
|
|
Related party payables, net |
|
|
69 |
|
|
|
70 |
|
|
Warrant liability |
|
|
1,033 |
|
|
|
– |
|
|
Insurance premium liability and other current liabilities |
|
|
333 |
|
|
|
986 |
|
|
Total current liabilities |
|
|
9,085 |
|
|
|
8,967 |
|
|
|
|
|
|
|
|
|
|
|
|
Loan due to Juvenescence, net of debt issuance costs, net of current portion |
|
|
6,756 |
|
|
|
6,062 |
|
|
TOTAL LIABILITIES |
|
|
15,841 |
|
|
|
15,029 |
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of June 30, 2022 and December 31, 2021 |
|
|
– |
|
|
|
– |
|
|
Common stock, $0.0001 par value, 100,000 shares authorized; and 37,945 and 37,941 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively |
|
|
4 |
|
|
|
4 |
|
|
Additional paid-in capital |
|
|
97,850 |
|
|
|
93,912 |
|
|
Accumulated deficit |
|
|
(111,072 |
) |
|
|
(105,748 |
) |
|
AgeX Therapeutics, Inc. stockholders’ deficit |
|
|
(13,218 |
) |
|
|
(11,832 |
) |
|
Noncontrolling interest |
|
|
(44 |
) |
|
|
(43 |
) |
|
Total stockholders’ deficit |
|
|
(13,262 |
) |
|
|
(11,875 |
) |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
$ |
2,579 |
|
|
$ |
3,154 |
|
|
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) |
||||||||||||||||
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
|
|
|
(unaudited) |
|
|||||||||||||
|
REVENUES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant revenues |
|
$ |
– |
|
|
$ |
11 |
|
|
$ |
– |
|
|
$ |
57 |
|
|
Other revenues |
|
|
12 |
|
|
|
26 |
|
|
|
17 |
|
|
|
36 |
|
|
Total revenues |
|
|
12 |
|
|
|
37 |
|
|
|
17 |
|
|
|
93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
6 |
|
|
|
13 |
|
|
|
7 |
|
|
|
16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
6 |
|
|
|
24 |
|
|
|
10 |
|
|
|
77 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
259 |
|
|
|
481 |
|
|
|
655 |
|
|
|
805 |
|
|
General and administrative |
|
|
1,338 |
|
|
|
1,748 |
|
|
|
2,998 |
|
|
|
3,770 |
|
|
Total operating expenses |
|
|
1,597 |
|
|
|
2,229 |
|
|
|
3,653 |
|
|
|
4,575 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on deconsolidation of LifeMap Sciences |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(1,591 |
) |
|
|
(2,205 |
) |
|
|
(3,643 |
) |
|
|
(4,392 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER EXPENSE, NET: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(863 |
) |
|
|
(274 |
) |
|
|
(1,434 |
) |
|
|
(517 |
) |
|
Unrealized loss on change in fair value of warrants |
|
|
(168 |
) |
|
|
– |
|
|
|
(255 |
) |
|
|
– |
|
|
Other income, net |
|
|
4 |
|
|
|
4 |
|
|
|
7 |
|
|
|
441 |
|
|
Total other expense, net |
|
|
(1,027 |
) |
|
|
(270 |
) |
|
|
(1,682 |
) |
|
|
(76 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS FROM CONTINUING OPERATIONS |
|
|
(2,618 |
) |
|
|
(2,475 |
) |
|
|
(5,325 |
) |
|
|
(4,468 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS FROM DISCONTINUED OPERATIONS |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(103 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS |
|
|
(2,618 |
) |
|
|
(2,475 |
) |
|
|
(5,325 |
) |
|
|
(4,571 |
) |
|
Net loss attributable to noncontrolling interest from continuing operations |
|
|
– |
|
|
|
1 |
|
|
|
1 |
|
|
|
2 |
|
|
Net loss attributable to noncontrolling interest from discontinued operations |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS ATTRIBUTABLE TO AGEX |
|
$ |
(2,618 |
) |
|
$ |
(2,474 |
) |
|
$ |
(5,324 |
) |
|
$ |
(4,562 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS PER COMMON SHARE: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC AND DILUTED |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
(0.07 |
) |
|
$ |
(0.07 |
) |
|
|
(0.14 |
) |
|
|
(0.12 |
) |
|
Discontinued operations |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
$ |
(0.07 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.12 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC AND DILUTED |
|
|
37,943 |
|
|
|
37,936 |
|
|
|
37,943 |
|
|
|
37,833 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AMOUNTS ATTRIBUTABLE TO AGEX: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations |
|
$ |
(2,618 |
) |
|
$ |
(2,474 |
) |
|
$ |
(5,324 |
) |
|
$ |
(4,466 |
) |
|
Loss from discontinued operations |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(96 |
) |
|
NET LOSS ATTRIBUTABLE TO AGEX |
|
$ |
(2,618 |
) |
|
$ |
(2,474 |
) |
|
$ |
(5,324 |
) |
|
$ |
(4,562 |
) |
|
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) |
||||||||
|
|
|
Six Months Ended June 30, |
|
|||||
|
|
|
2022 |
|
|
2021 |
|
||
|
|
|
(unaudited) |
|
|||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
Net loss attributable to AgeX from continuing operations |
|
$ |
(5,324 |
) |
|
$ |
(4,466 |
) |
|
Net loss attributable to noncontrolling interest |
|
|
(1 |
) |
|
|
(2 |
) |
|
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
Gain on deconsolidation of LifeMap Sciences |
|
|
– |
|
|
|
(106 |
) |
|
Gain on extinguishment of debt (Paycheck Protection Program Loan) |
|
|
– |
|
|
|
(437 |
) |
|
Unrealized loss on change in fair value of warrants |
|
|
255 |
|
|
|
– |
|
|
Amortization of intangible assets |
|
|
66 |
|
|
|
66 |
|
|
Amortization of debt issuance costs |
|
|
1,355 |
|
|
|
537 |
|
|
Stock-based compensation |
|
|
437 |
|
|
|
464 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts and grants receivable, net |
|
|
13 |
|
|
|
142 |
|
|
Prepaid expenses and other current assets |
|
|
614 |
|
|
|
472 |
|
|
Accounts payable and accrued liabilities |
|
|
(207 |
) |
|
|
(242 |
) |
|
Related party payables |
|
|
65 |
|
|
|
25 |
|
|
Insurance premium liability |
|
|
(653 |
) |
|
|
(611 |
) |
|
Other current liabilities |
|
|
(2 |
) |
|
|
(76 |
) |
|
Net cash used in operating activities from continuing operations |
|
|
(3,382 |
) |
|
|
(4,234 |
) |
|
Net cash used in operating activities from discontinued operations |
|
|
– |
|
|
|
(90 |
) |
|
Net cash used in operating activities |
|
|
(3,382 |
) |
|
|
(4,324 |
) |
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
Proceeds from the sale of LifeMap Sciences |
|
|
– |
|
|
|
466 |
|
|
Partial collection on loan due from LifeMap Sciences |
|
|
– |
|
|
|
250 |
|
|
Net cash provided by investing activities from continuing operations |
|
|
– |
|
|
|
716 |
|
|
Deconsolidation of cash and cash equivalents from discontinued operations |
|
|
– |
|
|
|
(50 |
) |
|
Net cash provided by investing activities |
|
|
– |
|
|
|
666 |
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
Draw down on loan facilities from Juvenescence |
|
|
3,500 |
|
|
|
3,500 |
|
|
Proceeds from the issuance of common stock |
|
|
– |
|
|
|
496 |
|
|
Net cash provided by financing activities from continuing operations |
|
|
3,500 |
|
|
|
3,996 |
|
|
Partial payment on loan due to AgeX from discontinued operations |
|
|
– |
|
|
|
(250 |
) |
|
Net cash provided by financing activities |
|
|
3,500 |
|
|
|
3,746 |
|
|
|
|
|
|
|
|
|
|
|
|
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH |
|
|
118 |
|
|
|
88 |
|
|
|
|
|
|
|
|
|
|
|
|
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: |
|
|
|
|
|
|
|
|
|
At beginning of the period |
|
|
634 |
|
|
|
577 |
|
|
At end of the period |
|
$ |
752 |
|
|
$ |
665 |
|
Contacts
Contact for AgeX:
Andrea Park
[email protected]
(510) 671-8620